Real-Time Definition of Non-Randomness in the Distribution of Genomic Events by Abel, U et al.
Real-Time Definition of Non-Randomness in the
Distribution of Genomic Events
Ulrich Abel
1,2, Annette Deichmann
1, Cynthia Bartholomae
1, Kerstin Schwarzwaelder
1, Hanno Glimm
1, Steven Howe
2, Adrian Thrasher
3,4,
Alexandrine Garrigue
5, Salima Hacein-Bey-Abina
5,6, Marina Cavazzana-Calvo
5,6, Alain Fischer
5,7, Dirk Jaeger
1, Christof von Kalle
1,8*,
Manfred Schmidt
1*
1Department of Translational Oncology, National Center for Tumor Diseases, Heidelberg, Germany, 2Department of Medical Biostatistics, Tumor
Center Heidelberg-Mannheim, Heidelberg, Germany, 3Molecular Immunology Unit, Institute of Child Health, University College London, London,
United Kingdom, 4Department of Clinical Immunology, Great Ormond Street Hospital NHS Trust, London, United Kingdom, 5INSERM Unit 768,
Ho ˆpital Necker and Faculte ´ de Me ´decine Universite ´ Rene ´ Descartes Paris V., Paris, France, 6De ´partement de Biothe ´rapies, Ho ˆpital Necker, Paris,
France, 7Unite ´ d’Immunologie et d’He ´matologie Pe ´diatriques, Ho ˆpital Necker, Paris, France, 8Division of Experimental Hematology, Cincinnati
Childrens Research Foundation, Cincinnati, Ohio, United States of America
Features such as mutations or structural characteristics can be non-randomly or non-uniformly distributed within a genome. So
far, computer simulations were required for statistical inferences on the distribution of sequence motifs. Here, we show that
these analyses are possible using an analytical, mathematical approach. For the assessment of non-randomness, our
calculations only require information including genome size, number of (sampled) sequence motifs and distance parameters.
We have developed computer programs evaluating our analytical formulas for the real-time determination of expected values
and p-values. This approach permits a flexible cluster definition that can be applied to most effectively identify non-random or
non-uniform sequence motif distribution. As an example, we show the effectivity and reliability of our mathematical approach
in clinical retroviral vector integration site distribution.
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of Genomic Events. PLoS ONE 2(6): e570. doi:10.1371/journal.pone.0000570
INTRODUCTION
With the sequences of complete genomes available [1–4], and
accelerating technologies for high-throughput sequencing [5]
genome wide sequence analyses of individual samples will soon
become reality. Comparative analyses of sequence composition
and sequence motif distribution have become central parts of
genome and transcriptome research, providing new insights on
evolution, physiology and medical diagnosis [6–15]. Our un-
derstanding of integrating viruses and related vectors in gene
therapy trials is an interesting example of such approaches. Since
the completion of the human and murine genome sequencing
projects the location of the vector in the cellular genome can be
defined precisely, allowing the determination of possible vector
integration induced effects on the surrounding genomic DNA
regions at the molecular level. Integration site analyses have
gained increasing interest with the dramatic development of
a retroviral vector-induced lymphoproliferative disease in 3
patients cured of X-linked severe combined immunodeficiency
(X-SCID) that was triggered by insertional activation of the proto-
oncogene LMO2 [16,17]. Meanwhile, insertion induced side
effects have been identified ranging from immortalization [18] to
clonal dominance [19–22] and even oncogenesis [23–25] in
a variety of gene therapy studies. These studies have in common
that a clustering of integration sites (IS) in certain genomic loci was
detectable, and likely provided a selective advantage for the
affected cell clone.
The clustering of integrations, termed common integration sites
(CIS), as an indicator for clone selection has already been used in
concerted retrovirus insertional mutagenesis studies that aimed to
identify new cancer genes by determining the gene configuration
near frequently affected integration site loci [26–28]. For CIS
determination, computer simulations were performed to assess
non-randomness of IS distribution in tumors [28]. To validate the
correctness of our mathematical approach defining non-random-
ness and non-uniform sequence motif distribution, we analyzed
the IS distribution and presence of CIS in 2 successful clinical
SCID-X1 studies [29,30, unpublished data]. We considered 2, 3
or 4 insertions as CIS of 2
nd,o f3
rd or 4
th order if they fell within
a 30 kb, 50 kb or 100 kb window of genomic sequence from each
other, respectively. Simultaneously, we performed computer
simulations written in open source ‘R’-language (http://cran.r-
project.org) for which a window of size dn (dn = the maximum
distance defining a CIS of order n) was shifted through the ordered
sequence of the IS. For each window W(j)=[IS(j),IS(j)+dn] it was
then counted how many CIS of order n including IS(j) as first
element were contained in W(j). We show that our mathematical
approach for defining biased IS distribution is comparable to the
output of computational simulations. It may have advantages in
performance of large quantities of individual analyses. Even if the
null hypothesis of random uniform allocation is not adequate, as it
is known from retroviral vector integration [31], our calculations
can address segments of the genome located between sites of
predilection for virus integration and can be extended to address
non-uniform sequence motif distributions.
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Part 1: Random uniform allocation of IS
For the purpose of this discussion, the unit of observation (location
and distance) is kilobasepair (kb). We assume that a number nis of
IS is randomly allocated (with a uniform distribution) to the
locations of a genome consisting of g kb. A CIS of order n is an n-
tuple of IS such that the maximum distance between the lowest
and highest position is no greater than a fixed bound.
Further terminology
dn, defining ‘‘size’’ or distance of a CIS of order n, i.e.
maximum permissible distance between any two mem-
bers of a CIS of order n.;
Pn, probability that a given (sub)set of n IS that are randomly
allocated form a CIS of order n
P(m,d), probability that a given subset of m randomly allocated
IS has a span (= maximum distance between any two
elements) of exactly d.
En, expected value of the number of CIS of order n
We start with the elementary observation that En equals Pn times
the number of subsets of IS consisting of n elements:
En~
nis
n
  
:Pn ð1Þ
Clearly,
Pn~
X dn
d~0
P(n,d) ð2Þ
It remains to determine P(n,d). First note that P(1,d)=0 for d.0.
Furthermore, for all m$1:
P(m,0)~
1
gm{1 ð3Þ
A recursive formula for P(m,d), d.0, can be derived by breaking
down the potential CIS of order m into subsets of m–1 elements
having a span of d’#d, to which an m-th IS is added such that the
maximum span is exactly d:
P(m,d)~
1
g
f
X d{1
d0~0
2:P(m{1,d0) ½  z(dz1)P(m{1,d)gzr ð4Þ
where r is a negligible correction term that arises because the
uncorrected recursion formula is strictly valid only for subsets of IS
that have a distance $d from the telomeres.
By mounting the recursive ladder (m=1,...,n), these formulas
successively yield P(n,d), Pn, and En. In particular, one easily
obtains (d.0):
P(2,d)&
2
g
P(3,d)&
6d
g2
P(4,d)&
12d2z2
g3
Plugging this into equations (2) and (1) yields for the expected
value En:
E2&
nis
2
  
(2d2z1)
g
E3&
nis
3
  
f3d3(d3z1)z1g
g2
E4&
nis
4
  
1z2d4f1z(d4z1)(2d4z1)g
g3
As shown in Table 1, our mathematical approximation
corresponds extremely well to the mean values found in 50000
simulation runs.
Statistical inferences, such as the calculation of p-values, can be
based on the observation that, under the null hypothesis (H0)o f
random uniform allocation of the IS, the number of CIS of order n
is (approximately) Poisson distributed with parameter l=En.
Thus, if the random variable X denotes the number of CIS of
order n, and X=k is observed in a trial, then the p-value P(X$k) of
this observation calculated under H0, i.e. from the Poisson
distribution Po(En), is given by
P(X§kjHo)~1{
X k{1
i~0
l
i
i!
e{l~P(x2ƒ2En),
where the random variable x
2 has a chi-square distribution with
2 k degrees of freedom [32,33].
The Poisson approximation to the true random distribution of
CIS is exceedingly close. In fact, if the number of simulation runs
is sufficiently high, the simulated distribution is virtually
undistinguishable from Po(En). In particular, both the expected
values and the p-values derived from Po(En) are nearly identical to
those obtained in computer simulations. The latter point is
apparent from Table 2, where for a final proof of principle of our
mathematical calculations, results of the analysis of our integration
data set retrieved from two clinical SCID-X1 therapy trials
[unpublished data] are given.
The p-value can be calculated by means of either of the
following commands (‘R’ code): 1–ppois(lambda=En, q=k–1) or
pchisq(df=2k, q=2En). Using the data of Table 2 (first line) 1–
ppois(lambda=0.19, q=2) or pchisq(df=6, q=0.38). In both
Table 1 Mean values for random CIS formation (1000 IS)
determined either with computer simulations or
mathematically.
......................................................................
Order of CIS Mean Value Mathematical Formula
Mean Value
Computer
Simulations
2
nd
E2&
1000
2
  
61
3:12:106 ~9:77
9.75
3
rd
E3& 1000
3
  
7651
(3:12:106)
2 ~0:13
0.13
4
th
E4& 1000
4
  
4:06:106
(3:12:106)
3 ~0:01
0.01
Simulations were performed with 50000 runs each. g, haploid size of the human
genome: 3.12 x 10
6 kb; dn, genomic window size [kb] for CIS of n
th order:
d2=30, d3=50, and d4=100; nis, number of (assumed) sampled integration
sites: 1000.
doi:10.1371/journal.pone.0000570.t001
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PLoS ONE | www.plosone.org 2 June 2007 | Issue 6 | e570instances, the result is 0.00099. Alternatively, the table of the
chisquare distribution with 6 degrees of freedom can be used to
look up the probability P(X#0.38). One should note that, for low
En, the p-value of a single observed CIS is virtually identical to En.
This implies that, for n.5, no p-values need to be calculated (and
hence no formulas are required for En, n.5), because even with an
extremely liberal definition of the CIS (d5=500) and a fairly high
number of IS (nis=1000) a single CIS of order 5 will be statistically
significant (p=0.027).
Part 2: Non-uniform allocation of IS
Defining non-randomness in the clustering of genomic events often
requires additional precautions as sequence structures of interest may
already have known specific distribution biases. In the case of our
clinical example (unpublished data), it is known that retroviral vectors
based on the murine leukaemia virus (MLV) tend to integrate into
gene coding regions preferentially near the transcriptional start site
(TSS) [34-36]. It is also proposed that additional factors, indeed
mostly unknown, may influence the accessibility of vectors to certain
genomic DNA regions [37]. Thus, the null hypothesis of random
uniform allocation of MLV IS distribution may not be adequate
according to the current ‘state of the art’, as has recently been argued
[31]. In line with this study,we portioned the genomeinto 2 adequate
areas that differ in the likelihood of getting targeted by vectors.
Further terminology
nTSS, number of TSS;
T5, an interval of +/-5kb around a TSS;
GT5, union of all T5
nis,Mix, nis,Comp, number of IS occuring in GT5 and in
the complement of GT5, respectively
ncis,GT5, ncis,Mix, ncis,Comp, number of CIS occurring in GT5, both
in GT5 and in the complement of GT5
and in the complement of GT5 only,
respectively.
Clearly, the expected value En of the number CIS of order n is
given by the following sum:
En~E(ncis,GT5)zE(ncis,Mix)zE(ncis,Comp) ð5Þ
In the following it will be shown how to calculate the terms on the
right side of (5). We start with the expected value of ncis,GT5 fore
what we assume that vector integration into any T5 occurs with
the same probability. Then
E(ncis,GT5)~nTSS:E(X), ð6Þ
where X is the number of CIS (among those occurring in GT5)
that occur in a fixed T5. Observing that i IS in a fixed T5 yield
i
n
  
CIS of order n in this T5 one easily obtains the expected
value of X
E(X)~P(X~n):1zP(X~nz1)
nz1
n
 !
z
P(X~nz2)
nz2
n
 !
z:::
ð7Þ
Since X is binomially distributed as , B(nis,GT5,1/nTSS),
P(X~i)~
nis,GU5
i
  
(
1
nTSS
)
i(
nTSS{1
nTSS
)
nis,GU5 ð8Þ
Merging equations (6)–(8) yields the desired formula for E(ncis,GT5):
E(ncis,GU5)~nTSS
X nis,GU5
i~n
nis,GU5
i
  
i
n
  
(
1
nTSS
)
i(
nTSS{1
nTSS
)
nis,GU5ð9Þ
If nis,GT5 is small compared to nTSS (undoubtedly, this is mostly
the case), terms of higher order can be neglected so that, because
(nTSS–1)/nTSS<1, formula (9) simplifies to
E(ncis,GU5)&nTSS
nis,GU5
n
  
(
1
nTSS
)
n~
nis,GU5
n
  
(
1
nTSS
)
n{1ð10Þ
Notice that formulas (6)–(10) do not depend on the spatial
distribution of the IS within the T5. (It is unnecessary to account
for the closeness of IS within T5 because any pair – or triple,
quadruple etc., for that matter – of IS within a T5 yields a CIS.)
Clearly, the expected value of ncis,Mix E(ncis,Mix) is not
independent of the distance between the IS and the TSS. Thus,
inevitably, assumptions regarding the spatial distribution for the IS
will influence its value. In the sequel, a formula for E(ncis,Mix) shall
be derived for the case n=2. As before, CIS of order 2 are defined
by a maximum distance d2 of 30kb between the IS.
If the TSS are indistiguishable with respect to the probability
distribution of the integrations, then
E(ncis,Mix)~nis,GT5:nis,Comp:nTSS:pMix, ð11Þ
where pMix denotes the probability that an arbitrary pair of IS
(with one element in GT5 and one element in the complement of
GT5) forms a CIS of order 2 around a fixed TSS.
We will assume that the distributions of IS within a T5 and
within +/-35 kb around a TSS are symmetric. Then, again using
kb as unit of distance,
pMix~2
ð 10
x~0
f(x)
ð 0
y~x{30
g(y)dydx: ð12Þ
In formula (12) the points x=0 and y=0 correspond to the
TSS-5; f(x) designates the probability density function of vector
Table 2 Comparative analysis of mean values and p-values
obtained computationally (‘Simulation’) or mathematically
(‘Formula’).
......................................................................
CIS IS MV Simulation MV Formula
p-Value
Simulation
p-Value
Formula
3 140 0.188 0.190 0.0009 0.001
1 134 0.175 0.174 0.16 0.16
4 102 0.100 0.101 0 3.9610
26
15 304 0.899 0.900 0 6.8610
214
102 572 3.200 3.193 0 ,10
216
The results refer to the presence of CIS detected in 2 clinical X-SCID gene
therapy studies [unpublished data]. Simulations were performed with 50000
runs on the haploid size of the human genome (3.12610
6 kb). P-values
estimated from simulations equal the proportion per 50000 runs in which the
number of CIS was at least as high as the number observed in the trials. The
genomic window size chosen for CIS of 2
nd order was 30kb. CIS, number of
identified CIS of 2
nd order in patient and control samples pre- and post-
transplant; IS, number of all unique identified integration sites in patient and
control samples pre- and post-transplant; MV, mean value.
doi:10.1371/journal.pone.0000570.t002
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PLoS ONE | www.plosone.org 3 June 2007 | Issue 6 | e570integrations in T5; and g(y) designates the corresponding density
function in [TSS-35, TSS-5].
Formula (12) shall be evaluated for two special cases:
Case 1: Vector integrations are uniformly distributed in GT5
and in the complement of GT5, respectively. I.e.,
f(x):1=(nTSS:10)
g(x):1=(g nTSS:10):
Solving the integrals in formula (12) we have
pMix~
400
10nTSS(g{10nTSS)
ð13Þ
Case 2: As above, vector integrations in the complement of
GT5 are assumed to be uniformly distributed. However, a tri-
angular distribution is assumed for f(x). The corresponding formula
is easily calculated:
f(x)~
x=(25nTSS) if xƒ5
(2=5{x=25)=nTSS if x§5
 
By plugging this into (12) we get
pMix~
170
3nTSS(g{10nTSS)
ð14Þ
It may be surprising that a triangular distribution in T5 results
in a higher expected value for ncis,Mix than a uniform distribution.
However, this becomes more plausible if one notes that a higher
value is also obtained if the IS are concentrated in an extreme
manner within the T5, viz. in a one-point distribution with total
mass in the TSS. In this special case (which is particularly easy to
evaluate), pMix = 50/(nTSS(g–nTSS)).
If, with respect to the formation of CIS, the complement of GT5
could be regarded as a continuum, the expected value of ncis,Comp
would be given by the formulas developed in Part 1 of this
contribution. In the case of retroviral (MLV) vectors, however, the
complement of GT5 has rather to be viewed as a partitioned set
consisting of approximately TSS disjoint intervals. It follows that
that the residual term on the right-hand side of equation (4) (Part
1) may no longer be negligible. Note however, the assumption of
a continuum clearly tends to lead to an overestimation of the
number of CIS, because the boundaries of the components reduce
the number of CIS occurring in their neighborhood. It follows that
the formulas derived in Part 1 form an upper bound for
E(ncis,Comp). In particular, the true p-values are less or equal to the
values calculated by means of the formulas derived in Part 1.
Therefore, any positive statements regarding statistical significance
remain valid. Moreover, the overestimation is probably fairly small
given that the sections of GT5 located between the TSS are mostly
rather wide compared to the length defining a CIS.
Indeed, the null hypothesis of non-uniform allocation for IS
distribution does not substantially change the results we have
obtained based on the hypothesis of a random uniform allocation
for CIS formation in our clinical samples (Table 2), as is shown in
Table 3.
Our mathematical formulas allow a reliable, straightforward
calculation of non-randomness in CIS and other genomic event
distributions under the null hypothesis of uniform and non-
uniform allocation. Using formula based workspaces (available on
request), expected values and p-values can be calculated with ease
in real-time. They may be preferable to computer simulations
when (routine) high-speed processing of large quantities of analyses
is needed. Our approach enables a closely problem-oriented,
highly exact evaluation of non-randomness that is useful for
assessing IS distribution in clinical trials and for assessing the
distribution of any sequence motif of interest in a natural or
artificial genome.
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